Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.
Block MS, Nelson GD, Chen J, Johnson S, Yang L, Flotte TJ, Grewal EP, McWilliams RR, Kottschade LA, Domingo-Musibay E, Markovic SN, Dimou A, Montane HN, Piltin MA, Price DL, Khariwala SS, Hui JYC, Erskine CL, Strand CA, Zahrieh D, Dong H, Hieken TJ.
Block MS, et al. Among authors: khariwala ss.
J Immunother Cancer. 2025 Apr 15;13(4):e011706. doi: 10.1136/jitc-2025-011706.
J Immunother Cancer. 2025.
PMID: 40234093
Free PMC article.
Clinical Trial.